Khalid Imran, Yamani Romaysaa M, Imran Maryam, Akhtar Muhammad Ali, Imran Manahil, Gul Rumaan, Khalid Tabindeh Jabeen, Wali Ghassan Y
John D. Dingell VA Medical Center, Detroit, MI, USA.
King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Acute Crit Care. 2021 Aug;36(3):223-231. doi: 10.4266/acc.2021.00388. Epub 2021 Jul 30.
Both coronavirus disease 2019 (COVID-19) and Middle East respiratory syndrome (MERS) can cause acute respiratory distress syndrome (ARDS); however, their ARDS course and characteristics have not been compared, which we evaluate in our study.
MERS patients with ARDS seen during the 2014 outbreak and COVID-19 patients with ARDS admitted between March and December 2020 in our hospital were included, and their clinical characteristics, ventilatory course, and outcomes were compared.
Forty-nine and 14 patients met the inclusion criteria for ARDS in the COVID-19 and MERS groups, respectively. Both groups had a median of four comorbidities with high Charlson comorbidity index value of 5 points (P>0.22). COVID-19 patients were older, obese, had significantly higher initial C-reactive protein (CRP), more likely to get trial of high-flow oxygen, and had delayed intubation (P≤0.04). The postintubation course was similar between the groups. Patients in both groups experienced a prolonged duration of mechanical ventilation, and majority received paralytics, dialysis, and vasopressor agents (P>0.28). The respiratory and ventilatory parameters after intubation (including tidal volume, fraction of inspired oxygen, peak and plateau pressures) and their progression over 3 weeks were similar (P>0.05). Rates of mortality in the ICU (53% vs. 64%) and hospital (59% vs. 64%) among COVID-19 and MERS patients (P≥0.54) were very high.
Despite some distinctive differences between COVID-19 and MERS patients prior to intubation, the respiratory and ventilatory parameters postintubation were not different. The higher initial CRP level in COVID-19 patients may explain the steroid responsiveness in this population.
2019冠状病毒病(COVID-19)和中东呼吸综合征(MERS)均可导致急性呼吸窘迫综合征(ARDS);然而,它们的ARDS病程和特征尚未进行比较,我们在本研究中对此进行评估。
纳入2014年疫情期间出现ARDS的MERS患者以及2020年3月至12月在我院住院的COVID-19合并ARDS患者,比较他们的临床特征、通气过程及结局。
COVID-19组和MERS组分别有49例和14例患者符合ARDS纳入标准。两组患者合并症中位数均为4种,查尔森合并症指数较高,均为5分(P>0.22)。COVID-19患者年龄更大、肥胖,初始C反应蛋白(CRP)显著更高,更有可能接受高流量吸氧试验,且插管延迟(P≤0.04)。两组插管后的病程相似。两组患者机械通气时间均延长,大多数接受了镇静剂、透析和血管活性药物治疗(P>0.28)。插管后的呼吸和通气参数(包括潮气量、吸入氧分数、峰压和平台压)及其3周内的变化相似(P>0.05)。COVID-19和MERS患者在重症监护病房(53%对64%)和医院(59%对64%)的死亡率非常高(P≥0.54)。
尽管COVID-19和MERS患者在插管前存在一些明显差异,但插管后的呼吸和通气参数并无不同。COVID-19患者较高的初始CRP水平可能解释了该人群对类固醇的反应性。